An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

Name: An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
Published: 2026
License: Public Domain

Second Affiliated Hospital of Soochow University · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

therapy

peripheral t-cell lymphoma refractory, therapy, azacitidine, chidamide, pd-1, interventional, early_phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

Related documents